Johnson & Johnson Elects Daniel Pinto to Board

An announcement from Johnson & Johnson ( (JNJ) ) is now available.

On June 10, 2025, Johnson & Johnson announced the election of Daniel Pinto to its Board of Directors, effective July 1, 2025. Pinto, who is the President of JPMorganChase, will also serve on the Audit and Compensation & Benefits Committees. His appointment is significant as JPMorganChase has been a major banking service provider to Johnson & Johnson, with the company paying approximately $39.2 million for various services in fiscal year 2024.

The most recent analyst rating on (JNJ) stock is a Hold with a $155.00 price target. To see the full list of analyst forecasts on Johnson & Johnson stock, see the JNJ Stock Forecast page.

Spark’s Take on JNJ Stock

According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.

Johnson & Johnson’s overall stock score reflects its strong financial performance and earnings call highlights, which are the most significant factors. The company enjoys high profitability and effective cash flow management, with positive growth projections from strategic investments. Technical indicators are neutral, with no strong trend. Valuation is reasonable, supported by a healthy dividend yield. However, the impact of a recent bankruptcy plan rejection and challenges in some product lines pose risks.

To see Spark’s full report on JNJ stock, click here.

More about Johnson & Johnson

Johnson & Johnson operates in the healthcare industry, providing a wide range of medical devices, pharmaceuticals, and consumer health products. The company is known for its focus on innovation and quality in healthcare solutions, serving a global market.

Average Trading Volume: 9,056,421

Technical Sentiment Signal: Strong Buy

Current Market Cap: $373B

For detailed information about JNJ stock, go to TipRanks’ Stock Analysis page.